What is Phase Focus?
Phase Focus Limited is a pioneering force in the life sciences sector, renowned for its patented quantitative phase imaging technology, most notably embodied in its flagship product, Livecyte. The company specializes in automated, non-invasive cell analysis, providing researchers with unparalleled insights into live cell behavior without the need for invasive labeling techniques. By bridging the gap between complex biological data and actionable research outcomes, Phase Focus has established itself as an essential partner for academic institutions and pharmaceutical organizations alike. Their market position is defined by a commitment to innovation, evidenced by multiple industry awards and a robust portfolio of versatile assays that address the evolving needs of the global oncology and cell biology markets.
How much funding has Phase Focus raised?
Phase Focus has raised a total of $6.8M across 3 funding rounds:
Unspecified
$1.2M
Unspecified
$571K
Unspecified
$5M
Unspecified (2008): $1.2M with participation from Fusion IP and Spirit Capital Partners
Unspecified (2009): $571K led by Maven Capital Partners UK, Yorkshire association of business angels, and South Yorkshire Investment fund
Unspecified (2012): $5M supported by Ombu Group
Key Investors in Phase Focus
Ombu Group
Ombu Group is a specialized investment firm that provides management support to advanced environmental and technology companies, focusing on long-term value creation through deep operational involvement.
Spirit Capital Partners
Spirit Capital is an independent private equity fund manager focused on realizing capital value for institutional and private investors within the UK SME segment through active asset management.
Maven Capital Partners UK
Maven Capital Partners is a prominent venture capital and private equity firm that provides growth capital to businesses, leveraging extensive industry expertise to drive corporate development.
What's next for Phase Focus?
With the support of its latest $5M capital injection, Phase Focus is well-positioned to accelerate its commercial expansion and deepen its penetration into the global life sciences market. The strategic focus will likely shift toward scaling the deployment of the Livecyte platform, enhancing software capabilities for high-throughput data analysis, and expanding its footprint in key international research hubs. As the company moves beyond its initial development phase, the emphasis will remain on maintaining its reputation for exceptional technical support and scientific rigor, ensuring that its imaging solutions remain at the forefront of the industry's technological evolution.
See full Phase Focus company page
